GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

APYX · Sep 30, 2023

Apyx Medical Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0000719135-23-000056General Corporate
Capex intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

1.45% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

30.86% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

31.40% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

94.23% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.gross_margin

66.62% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.operating_margin

-38.72% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

10.65% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

11.28% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History16 statesHistory building
Sep 30, 20220/7 normalizedLevel 3Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/8 normalizedLevel 3Jun 30, 20230/8 normalizedLevel 3Sep 30, 20230/8 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20247/9 normalizedLevel 3Dec 31, 20247/9 normalizedLevel 3Mar 31, 20257/9 normalizedLevel 3Jun 30, 20257/9 normalizedLevel 3Sep 30, 20258/9 normalizedLevel 3Dec 31, 20258/9 normalizedLevel 3Mar 31, 20269/9 normalizedLevel 3Jun 30, 20269/9 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Increased
Previous
1.15%
Current
1.45%
Delta
0.30%
Cash Generation Increased
Previous
-35.76%
Current
30.86%
Delta
66.62%
Inventory Pressure Increased
Previous
82.30%
Current
94.23%
Delta
11.93%
Margin Decreased
Previous
68.38%
Current
66.62%
Delta
-1.77%
Profitability Decreased
Previous
-9.10%
Current
-38.72%
Delta
-29.62%
R And D Intensity Increased
Previous
8.84%
Current
10.65%
Delta
1.82%
Sbc Intensity Increased
Previous
10.92%
Current
11.28%
Delta
0.36%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · APYX Fundamental State →Transitioned To · APYX Fundamental State →Transitioned To · APYX CAPEX_INTENSITY_INCREASED →Transitioned To · APYX CASH_GENERATION_INCREASED →Transitioned To · APYX INVENTORY_PRESSURE_INCREASED →Transitioned To · APYX MARGIN_DECREASED →Transitioned To · APYX PROFITABILITY_DECREASED →Transitioned To · APYX R_AND_D_INTENSITY_INCREASED →Transitioned To · APYX SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.